Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).
Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G. Torti C, et al. Among authors: mazzotta f. Int J Epidemiol. 2017 Apr 1;46(2):e12. doi: 10.1093/ije/dyv192. Int J Epidemiol. 2017. PMID: 26445966 No abstract available.
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
Trabattoni D, Lo Caputo S, Biasin M, Seminari E, Di Pietro M, Ravasi G, Mazzotta F, Maserati R, Clerici M. Trabattoni D, et al. Among authors: mazzotta f. Clin Diagn Lab Immunol. 2002 Sep;9(5):1114-8. doi: 10.1128/cdli.9.5.1114-1118.2002. Clin Diagn Lab Immunol. 2002. PMID: 12204968 Free PMC article. Clinical Trial.
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Mazzotta F, et al. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12626886 Clinical Trial.
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.
Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C; GenPherex Study Group of the MaSTeR Cohort. Torti C, et al. Among authors: mazzotta f. J Infect Dis. 2003 Jul 15;188(2):194-201. doi: 10.1086/376512. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854073
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
Scudeller L, Torti C, Quiros-Roldan E, Patroni A, Lo Caputo S, Moretti F, Mazzotta F, Donati E, Vivarelli A, Carosi G; GenPheRex Group of the MASTER Cohort. Scudeller L, et al. Among authors: mazzotta f. J Antimicrob Chemother. 2003 Nov;52(5):776-81. doi: 10.1093/jac/dkg456. Epub 2003 Oct 16. J Antimicrob Chemother. 2003. PMID: 14563897 Clinical Trial.
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Mazzotta F, Lo Caputo S, Pierotti P, Carosi G; GenPheRex PhenGen Study Groups of the MASTER Cohort. Torti C, et al. Among authors: mazzotta f. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1104-7. doi: 10.1097/00126334-200408150-00016. J Acquir Immune Defic Syndr. 2004. PMID: 15247566 Clinical Trial. No abstract available.
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Lo Caputo S, Tirelli V, Mazzotta F, Carosi G; MASTER Cohort GenPheRex Study Group; MASTER Cohort PhenGen Study Group. Torti C, et al. Among authors: mazzotta f. J Med Virol. 2004 Sep;74(1):29-33. doi: 10.1002/jmv.20142. J Med Virol. 2004. PMID: 15258965
Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).
Saracino A, Monno L, Locaputo S, Torti C, Scudeller L, Ladisa N, Antinori A, Sighinolfi L, Chirianni A, Mazzotta F, Carosi G, Angarano G. Saracino A, et al. Among authors: mazzotta f. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1587-98. doi: 10.1097/00126334-200412150-00011. J Acquir Immune Defic Syndr. 2004. PMID: 15577415 Clinical Trial.
315 results